Advertisement

Pathology & Oncology Research

, Volume 21, Issue 4, pp 1037–1043 | Cite as

Impact of prior azacitidine on the outcome of allogeneic hematopoietic transplantation for myelodysplastic syndrome

  • Gaku Oshikawa
  • Kousuke Yoshioka
  • Yukie Takahashi
  • Naoki Shingai
  • Shuntaro Ikegawa
  • Takeshi Kobayashil
  • Noriko Doki
  • Kazuhiko Kakihana
  • Kazuteru Ohashi
  • Hisashi Sakamaki
Research

Abstract

To clarify the clinical impact of prior use of azacitidine (AZA) on outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for myelodysplastic syndrome (MDS), we retrospectively reviewed the clinical outcomes of 15 MDS patients who were treated with AZA before allo-HSCT (AZA group). We compared the outcomes of these 15 patients with 52 MDS patients who were solely given the best supportive care (BSC) before allo-HSCT (BSC group). Although patients in the AZA group were older with higher International Prognostic Scoring System (IPSS) scores compared to patients in the BSC group, no significant differences were found between the two groups in overall survival (OS), disease-free survival (DFS), cumulative incidence of relapse (CIR) or non-relapse mortality. However, in patients with a higher IPSS score (Int-2/High), pre-transplant AZA may provide better OS and DFS and lower CIR. Acute graft-versus-host disease rates were similar between the two groups. These results should be reassuring to patients with high-risk MDS receiving AZA before allo-HSCT.

Keywords

Myelodysplastic syndrome Allogeneic hematopoietic stem cell transplantation Azacitidine 

Notes

Acknowledgements

We thank all of the physicians and nurses who cared for patients in this study.

Conflicts of interest

The authors declare no conflicts of interest.

References

  1. 1.
    Gyurkocza B, Deeg HJ (2012) Allogeneic hematopoietic cell transplantation for MDS: for whom, when and how? Blood Rev 26:247–254PubMedCentralCrossRefPubMedGoogle Scholar
  2. 2.
    Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R et al (2002) Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 20:2429–2440CrossRefPubMedGoogle Scholar
  3. 3.
    Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A et al (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10:223–232PubMedCentralCrossRefPubMedGoogle Scholar
  4. 4.
    Kim DY, Lee JH, Park YH, Kim SD, Choi Y, Lee SB et al (2012) Feasibility of hypomethylating agents followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome. Bone Marrow Transplant 47:374–379CrossRefPubMedGoogle Scholar
  5. 5.
    Damaj G, Duhamel A, Robin M, Beguin Y, Michallet M, Mohty M et al (2012) Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-Francophone des Myelodysplasies. J Clin Oncol 20:4533–4540CrossRefGoogle Scholar
  6. 6.
    Gerds AT, Gooley TA, Estey EH, Appelbaum FR, Deeg HJ, Scott BL (2012) Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS. Biol Blood Marrow Transplant 18:1211–1218PubMedCentralCrossRefPubMedGoogle Scholar
  7. 7.
    Field T, Perkins J, Huang Y, Kharfan-Dabaja MA, Alsina M, Ayala E et al (2010) 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 45:255–260CrossRefPubMedGoogle Scholar
  8. 8.
    Cogle CR, Imanirad I, Wiggins LE, Hsu J, Brown R, Scornik JC et al (2010) Hypomethylating agent induction therapy followed by hematopoietic cell transplantation is feasible in patients with myelodysplastic syndromes. Clin Adv Hematol Oncol 8:40–46PubMedGoogle Scholar
  9. 9.
    Yahng SA, Yoon JH, Shin SH, Lee SE, Cho BS, Lee DG et al (2013) Response to pretransplant hypomethylating agents influences the outcome of allogeneic hematopoietic stem cell transplantation in adults with myelodysplastic syndromes. Eur J Haematol 90:111–120CrossRefPubMedGoogle Scholar
  10. 10.
    Damaj G, Duhamel A, Robin M, Milpied N, Michallet M, Chevallier P et al (2013) Azacitidine versus best supportive care before non-myeloablative allogeneic stem cell transplantation for MDS: a study by the SFGM-TC. Leukemia Res 37(Suppl 1):S14–S15CrossRefGoogle Scholar
  11. 11.
    Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD et al (2006) Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108:419–425CrossRefPubMedGoogle Scholar
  12. 12.
    Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al (1976) Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 33:451–458CrossRefPubMedGoogle Scholar
  13. 13.
    Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079–2088PubMedGoogle Scholar
  14. 14.
    Giralt S (2005) Reduced-intensity conditioning regimens for hematologic malignancies: what have we learned over the last 10 years? Hematol Am Soc Hematol Educ Program 2005:384–389CrossRefGoogle Scholar
  15. 15.
    Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48(3):452–458PubMedCentralCrossRefPubMedGoogle Scholar
  16. 16.
    NCCN (2012) Clinical practice guidelines in oncology: Myelodysplastic syndromes version 2.2014. National Comprehensive Cancer Network, WashingtonGoogle Scholar
  17. 17.
    Sanchez-Abarca LI, Gutierrez-Cosio S, Santamaria C, Caballero-Velazquez T, Blanco B, Herrero-Sanchez C et al (2010) Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting. Blood 115:107–121CrossRefPubMedGoogle Scholar
  18. 18.
    Choi J, Ritchey J, Prior JL, Holt M, Shannon WD, Deych E et al (2010) In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. Blood 116:129–139PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2015

Authors and Affiliations

  • Gaku Oshikawa
    • 1
  • Kousuke Yoshioka
    • 1
  • Yukie Takahashi
    • 1
  • Naoki Shingai
    • 1
  • Shuntaro Ikegawa
    • 1
  • Takeshi Kobayashil
    • 1
  • Noriko Doki
    • 1
  • Kazuhiko Kakihana
    • 1
  • Kazuteru Ohashi
    • 1
  • Hisashi Sakamaki
    • 1
  1. 1.Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases CenterKomagome HospitalTokyoJapan

Personalised recommendations